PIM kinase inhibition induces epigenetically conditioned transcriptional changes, abnormal RNA splicing and DNA damage in diffuse large B-cell lymphoma cells

Diffuse large B-cell lymphoma (DLBCL) is characterized by pronounced molecular heterogeneity and remains incurable in a substantial fraction of patients who relapse or develop refractory disease following standard chemoimmunotherapy. PIM kinases are constitutively active oncogenic serine/threonine kinases implicated in lymphoma pathogenesis, transcriptional control and cell viability. However, the detailed molecular mechanisms by which PIMs regulate transcriptional programs, RNA metabolism, and genome stability remain largely unknown. Here, we demonstrate that PIM kinases maintain interphase phosphorylation of histone H3 at serine 10 (H3S10ph). Genetic or pharmacological inhibition of PIM kinase family leads to a global reduction of H3S10ph and other active histone marks, impaired RNA polymerase II elongation, and widespread transcriptional repression. Integrated epigenomic and transcriptomic analyses reveal that PIM family inhibition preferentially affects gene networks involved in RNA metabolism, including RNA processing, splicing, and RNA methylation pathways. PIM1 proximity proteome analysis identified multiple splicing-related proteins, and PIM1 co-association with SF3B1, XAB2, and EDC3 was confirmed using co-immunoprecipitation. Functionally, PIM kinase inhibition induces extensive alternative mRNA splicing abnormalities, promotes the accumulation of RNA-DNA hybrids (R-loops), and triggers DNA damage-associated checkpoint responses. Consistent with these findings, in preliminary in vitro drug combination studies, PIM inhibition synergizes with DNA-damaging chemotherapy and targeted inhibitors of the DNA damage response. Collectively, our results implicate PIM kinases in the regulation of transcription, RNA metabolism, and genome stability in DLBCL and provide a preclinical rationale for further investigation of combinations of PIM inhibitors with DNA-damaging agents or DNA damage response inhibitors.

Authors

Institutions

Publication Details

Journal
Oncogene
Published
2026-11-18
DOI
https://doi.org/10.1038/s41388-026-04044-9
Primary Topic
Lymphoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

PIM kinase inhibition induces epigenetically conditioned transcriptional changes, abnormal RNA splicing and DNA damage in diffuse large B-cell lymphoma cells

Ewa Kurtz, Marcin Kaszkowiak, Dominik Cysewski, Maciej Szydłowski et al.
Oncogene
Lymphoma Diagnosis and Treatment
article

PIM kinase inhibition induces epigenetically conditioned transcriptional changes, abnormal RNA splicing and DNA damage in diffuse large B-cell lymphoma cells

Ewa Kurtz, Marcin Kaszkowiak, Dominik Cysewski, Maciej Szydłowski, Ari M. Melnick, Patryk Górniak, Anna Paszek, Michał Pawlak, Aleksandra Żołyniak, Dorota Natalia Komar, Ewa Jabłońska, Nazli Serin, Ondřej Havránek, Przemysław Juszczyński, Filip Garbicz, Bjoern Chapuy, Kristýna Kupcová, Eliza Głodkowska‐Mrówka, Anna Rams, Dominika TRZMIEL, Julia Maroszek, Sabina Lichołai, Sonia Dębek, Mariia Stepanechko
article en

Abstract

Diffuse large B-cell lymphoma (DLBCL) is characterized by pronounced molecular heterogeneity and remains incurable in a substantial fraction of patients who relapse or develop refractory disease following standard chemoimmunotherapy. PIM kinases are constitutively active oncogenic serine/threonine kinases implicated in lymphoma pathogenesis, transcriptional control and cell viability. However, the detailed molecular mechanisms by which PIMs regulate transcriptional programs, RNA metabolism, and genome stability remain largely unknown. Here, we demonstrate that PIM kinases maintain interphase phosphorylation of histone H3 at serine 10 (H3S10ph). Genetic or pharmacological inhibition of PIM kinase family leads to a global reduction of H3S10ph and other active histone marks, impaired RNA polymerase II elongation, and widespread transcriptional repression. Integrated epigenomic and transcriptomic analyses reveal that PIM family inhibition preferentially affects gene networks involved in RNA metabolism, including RNA processing, splicing, and RNA methylation pathways. PIM1 proximity proteome analysis identified multiple splicing-related proteins, and PIM1 co-association with SF3B1, XAB2, and EDC3 was confirmed using co-immunoprecipitation. Functionally, PIM kinase inhibition induces extensive alternative mRNA splicing abnormalities, promotes the accumulation of RNA-DNA hybrids (R-loops), and triggers DNA damage-associated checkpoint responses. Consistent with these findings, in preliminary in vitro drug combination studies, PIM inhibition synergizes with DNA-damaging chemotherapy and targeted inhibitors of the DNA damage response. Collectively, our results implicate PIM kinases in the regulation of transcription, RNA metabolism, and genome stability in DLBCL and provide a preclinical rationale for further investigation of combinations of PIM inhibitors with DNA-damaging agents or DNA damage response inhibitors.

Oncogene
Broad Institute (US), Medical University of Białystok (PL), Charles University (CZ), Humboldt-Universität zu Berlin (DE), Josep Carreras Leukaemia Research Institute (ES), Instytut Hematologii i Transfuzjologi (PL), Abterra Biosciences (United States) (US), German Cancer Society (DE), Institute of Biochemistry and Biophysics, Polish Academy of Sciences (PL), Fundación Josep Carreras Contra la Leucemia (ES), Centre for Omic Sciences (ES), General University Hospital in Prague (CZ), Weill Cornell Medicine (US), Stiftung Charité (DE), EURECAT Centre Tecnològic de Catalunya (ES), Universitat Rovira i Virgili (ES), Massachusetts Institute of Technology (US), Freie Universität Berlin (DE), Charité - Universitätsmedizin Berlin (DE), Polish Academy of Sciences (PL)
Fundacja na rzecz Nauki Polskiej, Ministerstvo Zdravotnictví Ceské Republiky, Narodowe Centrum Nauki
Good health and well-being
Lymphoma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon